Therapy News and Research

RSS

Study results of triple combination therapy in patients with diabetes and hypertension presented at ADA 2010

Preliminary results of a pre-specified subgroup study analysis of patients with diabetes and hypertension demonstrated that the investigational triple combination therapy of olmesartan medoxomil / amlodipine / hydrochlorothiazide (40/10/25 mg) resulted in a statistically significant greater Least Squares mean reduction in blood pressure from baseline at week 12 (37.9/22.0 mm Hg versus 26.4-28.0/14.7-17.6 mm Hg, P less than or equal to 0.0013) as compared to corresponding dual combination therapy [olmesartan medoxomil (40 mg) / amlodipine (10 mg); olmesartan medoxomil (40 mg) / hydrochlorothiazide (25 mg); or amlodipine (10 mg) and hydrochlorothiazide (25 mg)].

1 Jul 2010

USPTO grants Semafore method patent for PI3K inhibitors

Semafore Pharmaceuticals today announced the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,745,485 entitled "Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways." This patent covers methods of inhibiting the spread of cancer in patients using phosphoinositide-3-kinase (PI3K) inhibitors alone or in combination with chemotherapeutic agents.

1 Jul 2010

Florida Biomedical Research Program awards $2M in grants to Scripps Research Institute scientists

The Florida Biomedical Research Program has awarded $2 million in biomedical research grants to three scientists from the Florida campus of The Scripps Research Institute.

1 Jul 2010

Nanostructured assemblies for dental application

Scientists are reporting an advance toward the next big treatment revolution in dentistry - the era in which root canal therapy brings diseased teeth back to life, rather than leaving a "non-vital" or dead tooth in the mouth. In a report in the monthly journal ACS Nano, they describe a first-of-its-kind, nano-sized dental film that shows early promise for achieving this long-sought goal.

1 Jul 2010

Researchers uncover potential drug treatment for noise-induced hearing loss

Researchers from the University of Auckland, New Zealand, have discovered that a potent new drug restores hearing after noise-induced hearing loss in rats. The landmark discovery found that injection of an agent called 'ADAC', activates adenosine receptors in cochlear tissues, resulting in recovery of hearing function. The finding paves the way for effective non-surgical therapies to restore hearing loss after noise-induced injury. Dr. Srdjan Vlajkovic and his team's work1 is published in a special edition of Springer's journal Purinergic Signalling, focusing on the inner ear.

1 Jul 2010

Researchers to study interventional endovascular therapy on symptoms and progression of MS

Buffalo medical researchers led by a team from the University at Buffalo Department of Neurosurgery, will embark on a landmark prospective randomized double-blinded study to test the safety and efficacy of interventional endovascular therapy -- dubbed "liberation treatment" -- on the symptoms and progression of Multiple Sclerosis.

1 Jul 2010

Commonly used type of bone marrow stem cell may help treat sepsis, new study suggests

A new study from researchers in Ottawa and Toronto suggests that a commonly used type of bone marrow stem cell may be able to help treat sepsis, a deadly condition that can occur when an infection spreads throughout the body. The study, published in the American Journal of Respiratory and Critical Care Medicine, shows that these cells can triple survival rates in an experimental model of sepsis.

1 Jul 2010

Researchers report no increased rate of heart attack in patients taking rosiglitazone

The diabetes drug rosiglitazone has been under intense scrutiny since a 2007 study in the New England Journal of Medicine looked at more than 40 clinical trials and linked the drug's use with increased risk of heart attack and death from heart disease.

1 Jul 2010

Sepracor announces preliminary results from OMNARIS HFA Phase III study for seasonal allergic rhinitis

Sepracor Inc. announced today the preliminary results of a large-scale, 671-patient Phase III study of OMNARIS® (ciclesonide) HFA, an aerosol nasal formulation of ciclesonide, for the treatment of seasonal allergic rhinitis (SAR) in adult and adolescent patients. In this study, OMNARIS HFA met its primary efficacy endpoint by demonstrating a statistically significant reduction versus placebo in the reflective total nasal symptom score averaged over a two-week treatment period.

1 Jul 2010

CDC issues new guidelines on detection of Mycobacterium tuberculosis infections

Today the United States Centers for Disease Control and Prevention issued new and important guidelines on the detection of Mycobacterium tuberculosis infections, the causative agent of tuberculosis. In these landmark guidelines, CDC advises that Interferon Gamma Release Assay blood tests are now preferred over the 100+-year-old tuberculin skin test for diagnosing TB infection in certain populations, including people who typically do not return for the necessary reading of TST results, and those who have received Bacille Calmette-Guerin as a vaccine or for cancer therapy

1 Jul 2010

CBio achieves recruitment milestone in XToll clinical trial

Australian drug development company CBio Limited today announced the achievement of a recruitment milestone in its clinical trial of XToll, the potential new-generation drug therapy which could provide safer and more effective treatment of autoimmune diseases such as rheumatoid arthritis.

1 Jul 2010

Biospherics acquires worldwide patent rights to Dtagatose from UKRF

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome, and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its wholly-owned subsidiary, Biospherics Incorporated, has signed a license agreement with the University of Kentucky Research Foundation (UKRF).

1 Jul 2010

Threshold Pharmaceuticals initiates Phase 2 clinical trial of TH-302 in patients with first line pancreatic cancer

Threshold Pharmaceuticals, Inc. today announced that it has initiated a multi-center, randomized, controlled, crossover Phase 2 clinical trial of TH-302 in combination with gemcitabine in patients with first line pancreatic cancer. TH-302 is a proprietary tumor selective Hypoxia-Activated Prodrug that specifically targets tumor hypoxia.

1 Jul 2010

ResponseDX: Lung genetic test panel launched to detect EML4-ALK gene variants in lung cancer patients

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced that it has expanded its ResponseDX: Lung genetic test panel to detect the presence of EML4-ALK gene variants in lung cancer patients. EML4-ALK fusion genes are present in about four percent of tumors from patients with non-small cell lung cancer.

1 Jul 2010

Cubist commences enrollment in Phase 2 study of CXA-201 for complicated intra-abdominal infections

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced the enrollment of the first patient in a Phase 2 study with CXA-201. This multicenter, double-blind, randomized, study will compare the safety and efficacy of intravenous CXA-201 with an active comparator in patients with complicated intra-abdominal Infections (cIAI). This international study is expected to enroll 120 patients.

1 Jul 2010

Neuralstem announces completion of $10 million registered direct offering

Neuralstem, Inc. (NYSE Amex: CUR) announced that it has completed its previously announced registered direct offering of $10 million of units to institutional investors. The units were priced at $2.80 and consisted of: (i) one share of common stock, and (ii) 3/4 common stock purchase warrant. The warrants have an exercise price of $3.25 and a term of three years. Net proceeds from this offering, after deducting placement agent fees and other offering expenses, total approximately $9.2 million. All of the securities were offered pursuant to an effective shelf registration statement.

1 Jul 2010

Vicept completes $16 million Series A financing

Vicept™ Therapeutics Inc., a privately held specialty biopharmaceutical company dedicated to developing the first effective topically applied therapy for erythema (facial redness) of rosacea, announced that it has secured $10 million to complete a total $16 million Series A financing. The Series A was led by Vivo Ventures, Sofinnova Ventures and Fidelity Biosciences.

30 Jun 2010

Proton Therapy USA, CareCapital form Proton Therapy Global Management

Proton Therapy USA and CareCapital plc announced today the formation of Proton Therapy Global Management (PTGM). The Company will design, develop and manage a global network of proton therapy centers, providing access to this specialized and highly effective treatment to the world's growing population of cancer patients. Proton therapy is a precise form of radiation treatment that has been very successful in treating a wide range of localized tumors, while leaving healthy tissue mostly intact.

30 Jun 2010

Fresenius Medical Care to acquire KNC and expand dialysis services business in Russian Federation

Fresenius Medical Care AG & Co. KGaA, the world's largest provider of dialysis products and services, is expanding its dialysis services business in the Russian Federation. The company announced today that it has signed an agreement to acquire KNC (KRAEVOY NEFROLOGICHESKIY CENTR), a private operator of dialysis clinics in Russia's Krasnodar region. The acquired operations will add approximately $25 million in annual revenue and are expected to be accretive to earnings in the first year after closing of the transaction.

30 Jun 2010

Celgene signs definitive merger agreement to acquire Abraxis BioScience

Celgene Corporation and Abraxis BioScience Inc. today jointly announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Abraxis BioScience. Under the terms of the merger agreement, each share of Abraxis BioScience common stock will be converted into the right to receive an upfront payment of $58.00 in cash and 0.2617 shares of Celgene common stock.

30 Jun 2010

Therapy News and Research

Study results of triple combination therapy in patients with diabetes and hypertension presented at ADA 2010

USPTO grants Semafore method patent for PI3K inhibitors

Florida Biomedical Research Program awards $2M in grants to Scripps Research Institute scientists

Nanostructured assemblies for dental application

Researchers uncover potential drug treatment for noise-induced hearing loss

Researchers to study interventional endovascular therapy on symptoms and progression of MS

Commonly used type of bone marrow stem cell may help treat sepsis, new study suggests

Researchers report no increased rate of heart attack in patients taking rosiglitazone

Sepracor announces preliminary results from OMNARIS HFA Phase III study for seasonal allergic rhinitis

CDC issues new guidelines on detection of Mycobacterium tuberculosis infections

CBio achieves recruitment milestone in XToll clinical trial

Biospherics acquires worldwide patent rights to Dtagatose from UKRF

Threshold Pharmaceuticals initiates Phase 2 clinical trial of TH-302 in patients with first line pancreatic cancer

ResponseDX: Lung genetic test panel launched to detect EML4-ALK gene variants in lung cancer patients

Cubist commences enrollment in Phase 2 study of CXA-201 for complicated intra-abdominal infections

Neuralstem announces completion of $10 million registered direct offering

Vicept completes $16 million Series A financing

Proton Therapy USA, CareCapital form Proton Therapy Global Management

Fresenius Medical Care to acquire KNC and expand dialysis services business in Russian Federation

Celgene signs definitive merger agreement to acquire Abraxis BioScience

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News